ライフサイエンスコーパス: transplant glomerulopathy

1 diated rejection with glomerular thrombi and transplant glomerulopathy.

2 dies, antibody-mediated rejection, and early transplant glomerulopathy.

3 as associated with more rapid progression to transplant glomerulopathy.

4 , or with podocyte depletion associated with transplant glomerulopathy.

5 ortantly, preventing ABMR and development of transplant glomerulopathy.

6 ctomy plus eculizumab patients had almost no transplant glomerulopathy.

7 body-mediated rejection (AMR) and subsequent transplant glomerulopathy.

8 rveillance and clinical biopsies that had no transplant glomerulopathy.

9 several cohorts of patients with and without transplant glomerulopathy.

10 ith scores indicative of fibrosis/atrophy or transplant glomerulopathy.

11 o non-HLA antibodies common to patients with transplant glomerulopathy.

12 fter transplant and strongly associated with transplant glomerulopathy.

13 ongly predicts graft loss when combined with transplant glomerulopathy.

14 gs were compared with 51 human biopsies with transplant glomerulopathy.

15 rulosclerosis, fibrointimal hyperplasia, and transplant glomerulopathy.

16 ously reported association of HCV with acute transplant glomerulopathy.

17 he predominant form of glomerular injury was transplant glomerulopathy.

18 n in humans and of a special subset of human transplant glomerulopathy.

19 ely for surgical reasons and one failed from transplant glomerulopathy after 5.8 yr with no histologi

20 ts were found in 8 of 51 human biopsies with transplant glomerulopathy after rigorous exclusion of im

21 proliferative changes and matrix remodeling (transplant glomerulopathy and capillaropathy); (b) EC pr

22 ve means of identifying patients at risk for transplant glomerulopathy and graft loss.

23 Coupled with absent transplant glomerulopathy and low rates of progressive I

24 cytokines in renal allograft recipients with transplant glomerulopathy and seem to be under the regul

25 ficant risk for antibody-mediated rejection, transplant glomerulopathy, and allograft loss (P<0.0001)

26 erstitial fibrosis, tubular atrophy, chronic transplant glomerulopathy, and chronic vascular rejectio

27 d examined associations with C4d deposition, transplant glomerulopathy, and graft failure.

28 more inflammation, were more likely to have transplant glomerulopathy, and had worse graft outcome.

29 The combined presence of C4d positivity, transplant glomerulopathy, and serum creatinine of >2.3

30 increase from baseline) or had minimal or no transplant glomerulopathy (Banff cg0-1).

31 Testing for DSA by C1q is more specific for transplant glomerulopathy (C1q: 81%, 95% CI 0.57-0.94; I

32 d a significantly higher prevalence of acute transplant glomerulopathy (Ctrl, 6%; R-HCV, 55%, P<.0001

33 Transplant glomerulopathy-free survival was also inferio

34 By contrast, patients who developed transplant glomerulopathy had 10- to 20-fold increased l

35 man leukocyte antigens type II (DSA II+) and transplant glomerulopathy has been clearly established,

36 95% CI 0.73-1; C1q: 88%, 95% CI 0.62-0.98), transplant glomerulopathy (IgG: 100%, 95% CI 0.73-1; C1q

37 vels of these cytokines were associated with transplant glomerulopathy (IL-1beta, P=0.019; IL-6, P=0.

38 There was no transplant glomerulopathy in biopsies from either group.

39 strongly associated with the development of transplant glomerulopathy in independent validation sets

40 noproliferative glomerulonephritis and acute transplant glomerulopathy in transplanted kidneys.

41 Transplant glomerulopathy increased over time after tran

42 Transplant glomerulopathy is associated with poor progno

43 A ABMR displayed increased proteinuria, more transplant glomerulopathy lesions, and lower glomeruliti

44 eat transplantation, mean arterial pressure, transplant glomerulopathy, microcirculation inflammation

45 Morphologic criteria for acute transplant glomerulopathy or proliferative glomeruloneph

46 litis was associated with the development of transplant glomerulopathy (OR=10.7, 95% CI=3.1-37.1, P<0

47 Patients who had no C4d deposition, transplant glomerulopathy, or microcirculation inflammat

48 CL2: Cr was significantly higher in IF+i and transplant glomerulopathy patients compared with normal

49 eloped de novo donor-specific antibodies and transplant glomerulopathy showed higher risk of graft lo

50 XM) kidney transplant recipients who develop transplant glomerulopathy (TG) and those who do not.

51 Graft survival and time to transplant glomerulopathy (TG) development were estimate

52 Transplant glomerulopathy (TG) is a diagnostic criterion

53 Transplant glomerulopathy (TG) is a histopathologic enti

54 ing precedes and predicts the development of transplant glomerulopathy (TG).

55 r and peritubular capillary inflammation and transplant glomerulopathy (TG).

56 ar factors associated with allograft loss in transplant glomerulopathy (TGP) patients.

57 C4d positivity and transplant glomerulopathy together portended exceptional

58 Transplant glomerulopathy (TxGN; cg>/=1) developed in 47

59 Transplant glomerulopathy (TxGN; cg>/=1) developed in 47

60 Transplant glomerulopathy was diagnosed by surveillance

61 Transplant glomerulopathy was diagnosed in 73 patients (

62 Transplant glomerulopathy was present in 25.0% of biopsi

63 pathophysiologic mechanisms associated with transplant glomerulopathy, we examined the expression of